POZEN Logo
Print Page   Close Window

Press Release

POZEN CEO To Present At the UBS Warburg Global Life Sciences Conference

CHAPEL HILL, N.C., Oct 1, 2002 (BUSINESS WIRE) -- POZEN Inc. (Nasdaq: POZN) announced today that John R. Plachetka, Pharm.D., the company's chairman, president and chief executive officer, will be speaking to investors at the UBS Warburg Global Life Sciences Conference on Tuesday, October 8, at 12:00 p.m. Eastern Time.

Dr. Plachetka will provide an overview of POZEN's business.

The presentation will be broadcast live and archived on POZEN's investor relations home page at www.pozen.com.

POZEN is a pharmaceutical development company committed to building a portfolio of products with significant commercial potential in select therapeutic areas. POZEN's initial focus is on developing products for migraine therapy, a global market expected to exceed $2.8 billion this year. The company's common stock is traded on The Nasdaq Stock Market under the symbol "POZN."

CONTACT:
POZEN Inc.
Matt Czajkowski
Chief Financial Officer
919-913-1030
or
Lisa Barthelemy
Director, Investor Relations
919-913-1044